When aessessing the rationale for switching from an originator anti-TNF to a biosimilar, single switch data is convincing for efficacy, safety, and comparable immunogenicity of the ant-TNF biosimilar. In what situations might

When aessessing the rationale for switching from an originator anti-TNF to a biosimilar, single switch data is convincing for efficacy, safety, and comparable immunogenicity of the ant-TNF biosimilar. In what situations might "multiple switching" apply?

When trying to assess the data and clinical rationale for switching from an originator anti-TNF to a biosimilar, it appears that the single switch data is convincing in supporting the efficacy, safety, and comparable immunogenicity of the ant-TNF biosimilar. In what situations might “multiple switching” apply and why do we need this data?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Stanley Cohen, MD

Stanley Cohen, MD

Clinical Professor
Department of Internal Medicine
UT Southwestern Medical Center
Co-Director of the Division of Rheumatology
Presbyterian Hospital
Dallas, Texas